5 Pulmonology Headlines You Missed in July

July 2026 brought a diverse set of pulmonology updates spanning clinical guidelines, pipeline data, and emerging science across interstitial lung disease, COPD, and pulmonary vascular disease. One of the month’s most clinically significant development came from a post hoc pooled analysis of the FIBRONEER-IPF and FIBRONEER-ILD trials, which found that nerandomilast (Jascayd; Boehringer Ingelheim) — the oral PDE4B inhibitor approved last year for IPF and progressive pulmonary fibrosis — reduced the risk of death by 33% at the 9 mg twice-daily dose (HR, 0.67; P =.009) and 43% at 18 mg twice daily (HR, 0.57; P <.001) vs placebo in pooled data; the mortality reduction reached nominal significance in FIBRONEER-ILD at both doses (HR, 0.51) but not in FIBRONEER-IPF as a standalone trial. Because the key secondary composite endpoint was not met in either trial at the first database lock, stopping hierarchical testing, all mortality P values are nominal rather than confirmatory — an important caveat that limits the regulatory implications but does not diminish the clinical interest in a drug already on the market.